Fulton Breakefield Broenniman LLC Exelixis, Inc. Transaction History

Fulton Breakefield Broenniman LLC

  • $1.41 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2019

Oct 17, 2019
SELL
$17.68 - $22.65 $272,254 - $348,787
-15,399 Closed
0 $0
Q2 2019

Jul 25, 2019
BUY
$18.93 - $24.75 $10,600 - $13,860
560 Added 3.77%
15,399 $329,000
Q1 2019

Apr 17, 2019
SELL
$19.6 - $24.76 $20,384 - $25,750
-1,040 Reduced 6.55%
14,839 $353,000
Q4 2018

Feb 05, 2019
BUY
$13.65 - $21.8 $216,748 - $346,162
15,879 New
15,879 $312,000

Others Institutions Holding EXEL

# of Institutions
502
Shares Held
243M
Call Options Held
2.54M
Put Options Held
2.29M
View Full List

About EXELIXIS, INC.

EXEL Quotes by TradingView
  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Fulton Breakefield Broenniman LLC Portfolio

Follow Fulton Breakefield Broenniman LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fulton Breakefield Broenniman LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fulton Breakefield Broenniman LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email